News

DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk in Arthritis


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

DANBIO is financially supported by grants from the Danish Rheumatism Association and the Danish Cancer Society. Dr. Hetland has acted as a consultant to Roche, and has received grants and research support on behalf of DANBIO from Abbott, BMS, Centocor, Roche, Schering-Plough, UCB-Nordic, and Wyeth. Dr. Dreyer had no disclosures. Dr. Schett was not involved in the study.

Pages

Recommended Reading

Tofacitinib Scores Well on Patient Reports
MDedge Internal Medicine
A Closer Look at Role of MRI in SpA
MDedge Internal Medicine
3e Initiative Proposes IA Pain Management Recommendations
MDedge Internal Medicine
BSRBR: Rituximab Effective; Disease Activity, Functional Status Predict Response
MDedge Internal Medicine
Obesity May Eliminate Need for DXA Osteoporosis Screening
MDedge Internal Medicine
Consider Celiac Disease in Autoimmune Disorder Patients
MDedge Internal Medicine
CDC: Obesity With Arthritis Hinders Physical Activity
MDedge Internal Medicine
Nonrheumatologic Off-Label Uses for Biologics Growing
MDedge Internal Medicine
Hypothyroidism in Arthritis Patients Drives Up Cardiovascular Risk
MDedge Internal Medicine
Gout Raises MI Risk in Young, Low Risk
MDedge Internal Medicine